Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD

NCT02586155 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2425

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2
Coronary Artery Disease

Interventions

DRUG: Apabetalone
DRUG: Placebo
DRUG: Atorvastatin
DRUG: Rosuvastatin

Sponsor

Resverlogix Corp

Collaborators

[object Object]
[object Object]
[object Object]